BTC 
ETH 
XRP
SOL 
DOGE - This topic is empty.
-
Posts
-
Bayer had a busy start to the week: the FDA granted Priority Review to its Lynkuet drug (elinzanetant) for a new indication, while a Delaware federal court refused to toss out Bayer’s mRNA patent lawsuits. Two very different stories — one about growth, one about litigation — but both matter for how the market prices the German group’s risk/reward.
What Happened
The FDA granted Priority Review to Lynkuet (elinzanetant) for moderate to severe vasomotor symptoms — hot flashes and night sweats — in women on endocrine therapy for hormone receptor-positive breast cancer. The application rests on data from the Phase III OASIS-4 trial. The designation is reserved for drugs the agency views as a meaningful advance over existing options, and it shortens the review timeline.
Separately, Judge William Bryson in Delaware declined to dismiss Bayer’s mRNA patent cases against Pfizer, BioNTech, and Moderna. Filed via Bayer’s Monsanto subsidiary, the suits allege the companies’ COVID-19 vaccines infringed a patent on mRNA stabilization technology with roots in 1980s agricultural research. The defendants argued the patent was invalid or not infringed; the judge rejected dismissal at this early stage. This is procedural only — no ruling on the merits, and a final resolution could take years, via trial or a licensing deal.
Key figures at a glance:
- ~1.2–1.3% — Bayer’s intraday share gain, to roughly EUR 50.80
- ~37% — Bayer stock’s gain since the start of the year
- EUR 2 billion — hybrid bonds placed by Bayer as part of its portfolio streamlining
- Phase III OASIS-4 — trial underpinning the Priority Review application
For context, Bayer sold its Stivarga cancer drug to Grünenthal on September 21 and launched EUR 2 billion in hybrid bonds. A Missouri hearing on approval of Bayer’s Roundup settlement began about two weeks ago, with a ruling still pending.
Why It Matters
Lynkuet targets a genuinely underserved population: breast cancer patients on endocrine therapy cannot take hormone therapy for hot flashes, so a non-hormonal option fills a real gap. Priority Review signals the FDA sees a potential step forward — a possible growth driver for Bayer’s pharma division as it concentrates on core areas.
The mRNA suits surviving dismissal keeps a licensing-or-settlement option alive, but with years of legal runway it is best viewed as a long-shot call option. The bigger near-term overhang remains Roundup — the Missouri ruling on the settlement will likely move the stock far more than the Delaware procedural win.
What to Watch
Watch for the full OASIS-4 data readouts and any FDA advisory committee activity — no PDUFA target date was disclosed. The Missouri ruling on the Roundup settlement is the next legal catalyst, with any appeal in the Delaware mRNA cases running well behind it.
Related reading: more big-cap pharma coverage in our Market News forum, plus the latest sector headlines at Market News.
Discussion question: How do you weigh Bayer’s pharma pipeline upside against its legal overhangs — does Lynkuet’s Priority Review make the stock’s 37% year-to-date run a reason to take profit, or a reason to stay long? Share your take below.
Source: ad-hoc-news.de
Auto-posted by the Bull Lounge news desk.
Not financial advice.Log in to vote
